
Eleventh John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease 11-12 March 2016



11 March 2016

Chairs: Sheila Haworth, University College London, London, UK Jim White, University of Rochester, Rochester, USA

Refreshments

Meeting Adjournment

Reception at the Royal Society

Pulmonary Hypertension in the Developing World

Sheila Haworth, University College London, London, UK

How Do Rehabilitation Programs Improve Patients with PAH?

Jim White, University of Rochester, Rochester, USA

Life After Pump: Can We Transition Any Patients From Pumps to Pills?

Ekkehard Gruenig, University of Heidelberg, Heidelberg, Germany

The Broad Spectrum of Pulmonary Hypertension: Challenging the Clinical Classification

Ex Vivo Lung Perfusion to Improve Outcome in Lung Transplantation

Stephan Rosenkranz, University of Cologne, Cologne, Germany

Shaf Keshavjee, Toronto General Hospital, Toronto, Canada

12 March 2016

8.30-9.30am	Registration, tea and coffee	Trials and Targets in PAH	
9.30am	Welcome Chris Thiemermann, Queen Mary University of London, London, UK	Chairs: Irene Lang, University of Vienna, Vienna, Austria Lewis Rubin, University of California San Diego, San	
Recent De	evelopments in PAH	9.30am	New Guidelines for PAH Marc Humbert, Université Paris-Sud, Paris, Fi
Chairs: Stephan Rosenkranz, University of Cologne, Cologne, Germany Brendan Whittle, Queen Mary University of London, London, UK		10.00am	Pulmonary Hypertension Trials: How Can We Do I Ioana Preston, Tufts University, Boston, USA
9.45am	Actions of Treprostinil on VEGF-A Formation by Mesenchymal Stem Cells David Smadja, Georges Pompidou European Hospital, Paris, France	10.30am	Effectiveness of Oral Prostacyclin Therapies for P Lewis Rubin, University of California San Dieg
10.15am	Microparticles and Pulmonary Hypertension Francoise Dignat George, Aix-Marseille University, Marseille, France	11.00am	Treating PAH by Targeting BMPR2 Nicholas W. Morrell, University of Cambridge
10.45am	FoxO1 Transcription Factor in Pulmonary Hypertension Soni Pullamsetti, University of Giessen, Giessen, Germany	11.30am	Refreshments
11.15am	Refreshments	Debate: Combination Therapy Should Be Us	
		Moderater: Robert Naeije, Université Libre de Bruxelles, Brus	
Aspects of Survival and Heart Failure in PAH		12.00pm	Pro Debate Olivier Sitbon, Université Paris-Sud, Paris, Fra
11.40am	Survival in PAH Raymond Benza, Allegheny Health Network, Pittsburgh, USA	12.20pm	Con Debate Luke Howard, Imperial College, London, UK
12.10pm	Pulmonary Hypertension in Left Heart Failure: Right Ventricular Function and Survival Irene Lang, University of Vienna, Vienna, Austria	12.40pm	Debate Discussion
12 40nm		1.00pm	Lunch
12.40pm	Lunch		
Clinical As	spects of PAH	2.30pm	Close of meeting

2.00pm

2.30pm

3.00pm

3.30pm

4.00pm

4.30pm

5.00pm

5.00pm

n Diego, USA

France

o Better?

r PAH **iego, San Diego, USA**

ge School of Clinical Medicine, Cambridge, UK

Jsed Immediately in all Patients with PAH **russels, Belgium**

France

11-12 March 2016 Royal Society, London, UK

Faculty Chair

Professor Chris Thiemermann, Queen Mary University of London, London, UK

Faculty


Professor Sheila Haworth, University College London, London, UK Professor Irene Lang, University of Vienna, Vienna, Austria Professor Robert Naeije, Université Libre de Bruxelles, Brussels, Belgium Professor Stephan Rosenkranz, University of Cologne, Cologne, Germany

Allocated 8 CPD credits by Royal College of Physicians

www.williamharvey.co.uk

Professor Lewis Rubin, University of California San Diego, San Diego, USA Professor James White, University of Rochester Medical Center, Rochester, USA

Professor Brendan Whittle, Queen Mary University of London, London, UK



William Harvey Research Limited John Vane Science Centre Charterhouse Square London EC1M 6BQ United Kingdom Tel: +44 (0)20 7882 8808 email: whrl@qmul.ac.uk

Registered in England – Registration No 2437946 Registered office: Charterhouse Square, London EC1M 6BQ